Xuelan Zhou

Structural characterization of HCoV-229E and H163A main protease (Mpro) interactions with the inhibitor narlaprevir

Narlaprevir, originally developed as a clinical-stage inhibitor of the hepatitis C virus (HCV) NS3/4A protease, has recently demonstrated potent inhibitory activity against the SARS-CoV-2 main protease (M pro ), with its co-crystal structure already resolved. To elucidate the mec...